ISSN: 2161-0711

Médecine communautaire et éducation à la santé

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Study on Evaluation Indicators of Protective Effect and Eligibility Criteria of Phase III Clinical Trial of Vaccine

Ruyun Wang

The phase Ⅲ vaccine trial is a field evaluation. It is of important value to study the current evaluation indicators of vaccine protection effect and the existing eligibility criteria for testing vaccines that are affected by local public health measures. We derive the magnification between the statistical bias of the incidence in phase Ⅲ vaccine trials and the bias of the current vaccine protection rate. This magnification is directly controlled by the public health protection rate, the greater the public health protection rate, the greater the magnification times. It reveals the internal mechanism that the current vaccine protection rate is not suitable for the evaluation of vaccines. The correctness of the conclusions was further verified using data from the phase Ⅲ trial of the available COVID-19 vaccine.

An equivalent relationship with the existing eligibility criteria for testing vaccines was established by using the comprehensive protection rate with comparability and computational stability. It is proved that with the increase of public health protection rate, the existing eligibility criteria for testing vaccines will lead to the difficulty of vaccine approval.